Grace Therapeutics, Inc. (NASDAQ: GRCE)

Acasti Pharma Inc., commonly recognized by its ticker symbol ACST, is a prominent player in the biopharmaceutical industry. The company's primary focus lies in the development and commercialization of products intended for rare and orphan diseases. These products are designed to enhance clinical outcomes, leveraging the company's innovative drug delivery technologies.

Acasti Pharma's operations span across various stages of pharmaceutical development, from research and development to clinical trials and eventual commercialization. The company's portfolio includes three clinical-stage drug candidates: GTX-104, GTX-102, and GTX-101. These candidates are each tailored to address specific rare and orphan diseases, demonstrating Acasti Pharma's commitment to this sector.

GTX-104 is a novel, injectable formulation of nimodipine for intravenous infusion, primarily targeting aneurysmal subarachnoid hemorrhage (aSAH) patients. This product holds the potential to offer improved bioavailability and reduced inter- and intra-subject variability compared to the current standard of care, oral nimodipine. The company has successfully completed the dosing of the first patient in the STRIVE-ON Phase 3 clinical trial, a significant step towards evaluating GTX-104's safety and efficacy.

GTX-102 is a novel, concentrated oral-mucosal spray of betamethasone, designed for the treatment of Ataxia Telangiectasia (A-T). This is a rare genetic progressive autosomal recessive neurodegenerative disorder, for which there is currently no FDA-approved treatment. GTX-102 holds the potential to provide clinical benefits in decreasing A-T symptoms, and the company plans to conduct further clinical development for this product candidate.

GTX-101 is a topical bioadhesive film-forming bupivacaine spray, developed for the treatment of Postherpetic Neuralgia (PHN), a chronic pain condition that can occur following shingles. This product holds the potential to offer improved pain relief and reduced side effects compared to current treatments for PHN.

Acasti Pharma's management team boasts extensive experience in drug formulation, drug delivery research and development, clinical and pharmaceutical development, regulatory affairs, and business development. This expertise, coupled with a strong intellectual property portfolio of over 40 granted and pending patents in various jurisdictions worldwide, positions the company competitively within the industry.

The company's customers primarily consist of hospitals and healthcare systems that treat patients with rare and orphan diseases. Acasti Pharma works closely with these customers to ensure its products meet their needs and are used effectively.

In terms of its product portfolio, Acasti Pharma has a strong emphasis on developing and commercializing pharmaceutical products for rare and orphan diseases. This focus, combined with its innovative drug delivery technologies, provides the company with a competitive edge in the industry.